Zynerba Pharmaceuticals Inc (ZYNE) CFO Buys $103,064.00 in Stock

Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) CFO James E. Fickenscher bought 5,200 shares of Zynerba Pharmaceuticals stock in a transaction that occurred on Friday, May 12th. The shares were acquired at an average cost of $19.82 per share, for a total transaction of $103,064.00. Following the acquisition, the chief financial officer now owns 12,200 shares in the company, valued at approximately $241,804. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) traded down 3.84% during midday trading on Friday, hitting $18.05. 382,240 shares of the stock traded hands. The firm’s 50-day moving average is $21.29 and its 200-day moving average is $18.42. Zynerba Pharmaceuticals Inc has a 52-week low of $6.31 and a 52-week high of $25.95. The company’s market cap is $238.51 million.

Zynerba Pharmaceuticals (NASDAQ:ZYNE) last released its quarterly earnings results on Tuesday, May 9th. The company reported ($0.60) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.55) by $0.05. Analysts predict that Zynerba Pharmaceuticals Inc will post ($2.43) EPS for the current year.

COPYRIGHT VIOLATION NOTICE: This piece was posted by sleekmoney and is owned by of sleekmoney. If you are reading this piece on another website, it was stolen and republished in violation of United States & international copyright legislation. The legal version of this piece can be accessed at https://sleekmoney.com/zynerba-pharmaceuticals-inc-zyne-cfo-buys-103064-00-in-stock/1836562.html.

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. J. Goldman & Co LP purchased a new position in Zynerba Pharmaceuticals during the fourth quarter worth $1,113,000. GSA Capital Partners LLP purchased a new position in Zynerba Pharmaceuticals during the fourth quarter worth $214,000. Perceptive Advisors LLC purchased a new position in Zynerba Pharmaceuticals during the fourth quarter worth $13,128,000. Putnam Investments LLC purchased a new position in Zynerba Pharmaceuticals during the fourth quarter worth $725,000. Finally, Rothschild Investment Corp IL boosted its position in Zynerba Pharmaceuticals by 95.0% in the first quarter. Rothschild Investment Corp IL now owns 45,620 shares of the company’s stock worth $917,000 after buying an additional 22,225 shares during the period. Institutional investors and hedge funds own 15.00% of the company’s stock.

A number of brokerages have issued reports on ZYNE. Canaccord Genuity set a $35.00 price target on shares of Zynerba Pharmaceuticals and gave the stock a “buy” rating in a report on Saturday, May 13th. Roth Capital set a $30.00 price target on shares of Zynerba Pharmaceuticals and gave the stock a “buy” rating in a report on Saturday, May 13th. Cantor Fitzgerald reissued a “buy” rating and issued a $28.00 price target on shares of Zynerba Pharmaceuticals in a report on Tuesday, May 9th. Oppenheimer Holdings Inc. set a $29.00 price target on shares of Zynerba Pharmaceuticals and gave the stock a “buy” rating in a report on Saturday, April 1st. Finally, Zacks Investment Research lowered shares of Zynerba Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, March 29th. One research analyst has rated the stock with a hold rating and eight have given a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus target price of $31.44.

About Zynerba Pharmaceuticals

Zynerba Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company is engaged in developing and commercializing transdermal synthetic cannabinoid treatments for patients with high unmet needs. Its development pipeline includes two product candidates: ZYN002 and ZYN001. ZYN002 is a synthetic cannabidiol (CBD), which is a non-psychoactive cannabinoid, formulated as a patent-protected permeation-enhanced gel for transdermal delivery through the skin and into the circulatory system.

5 Day Chart for NASDAQ:ZYNE

This story was originally published by sleekmoney (https://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://sleekmoney.com/zynerba-pharmaceuticals-inc-zyne-cfo-buys-103064-00-in-stock/1836562.html

Receive News & Ratings for Zynerba Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zynerba Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.

 

Leave a Reply

Your email address will not be published. Required fields are marked *